NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation (“Bausch + Lomb” or the “Company”) (NYSE: BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Bausch + Lomb Corporation (“BLCO” or the “Company”) (NYSE: BLCO) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of Bausch + Lomb Corporation (“BLCO” or the “Company”) (NYSE: BLCO) investors concerning the Company’s possible violations of federal securities laws.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
The Law Offices of Frank R. Cruz announces an investigation of Bausch + Lomb Corporation (“BLCO” or the “Company”) (NYSE: BLCO) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced CE Mark approval for the LuxLife full range of vision intraocular lens (IOL). The preloaded IOL provides patients with natural, continuous vision, from distance to near. Today’s announcement reinforces Bausch + Lomb’s commitment to equip cataract surgeons with choices to fit the right lens to the right patient following the recent launches of enVista® Envy™ full range of vision lenses in the United States and Canada and enVista Aspire™ intermediate-optimized IOLs in Europe.
Shares of eyecare company Bausch + Lomb (NYSE:BLCO)
fell 21.2% in the morning session after the company reported weak first quarter 2025 results: constant currency revenue fell short of Wall Street's estimates, leading to an EPS miss. On the other hand, it was good to see Bausch + Lomb provide full-year revenue guidance that slightly beat analysts' expectations, although raising full-year revenue guidance after missing on revenue often raises questions. Overall, this quarter could have been better.
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Eyecare company Bausch + Lomb (NYSE:BLCO) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3.5% year on year to $1.14 billion. On the other hand, the company’s full-year revenue guidance of $5.05 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP loss of $0.15 per share was significantly below analysts’ consensus estimates.
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2025 financial results.
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has identified the event that led to its recent voluntary recall of intraocular lenses (IOLs) on the enVista platform. Now that the cause and affected lots have been confirmed, the company will return these models to market.
Bausch + Lomb has gotten torched over the last six months - since October 2024, its stock price has dropped 41.5% to $12.06 per share. This might have investors contemplating their next move.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Bausch + Lomb (NYSE:BLCO) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Haemonetics (NYSE:HAE) and the best and worst performers in the medical devices & supplies - specialty industry.
Shares of eyecare company Bausch + Lomb (NYSE:BLCO)
fell 6.7% in the morning session after Wells Fargo downgraded the stock's rating from Buy to Hold. The firm cited concerns related to the "voluntary recall" of certain implantable eye lenses reported the previous day.
Shares of eyecare company Bausch + Lomb (NYSE:BLCO)
fell 10.6% in the afternoon session after the company announced the voluntary recall of intraocular lenses on its enVista platform. The recall was due to the reports of toxic anterior segment syndrome (TASS, a potential complication in any cataract surgery).
The recall may raise short-term concerns regarding product safety and regulatory scrutiny. Though the company emphasized that the reported cases of TASS involved only an extremely small fraction of implanted lenses.
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced a voluntary recall of intraocular lenses (IOLs) on its enVista platform. This action was taken out of an abundance of caution after the company received reports of complications, the cause of which could not immediately be explained.
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 30, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 5.9%. This performance was discouraging since the S&P 500 held steady.
